Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | CAR-NK and CAR-T for MCL

Michael Wang • 8 Jun 2021
EHA 2021
Lymphoma Mantle Cell Lymphoma Brexucabtagene autoleucel CAR-NK CAR-T

Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy, highlighting promising activity observed in B-cell lymphomas including B-cell acute lymphoblastic leukemia (B-ALL). Prof. Wang also gives an overview of the CAR T-cell therapies currently under investigation for mantle cell lymphoma (MCL), highlighting the approval of brexucabtagene autoleucel for relapsed/refractory MCL. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Michael Wang

3:37
SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL
Michael Wang • 11 Dec 2023
1:57
Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang • 6 Sep 2023
1:18
BRUIN study cohort update: pirtobrutinib for patients with MCL
Michael Wang • 6 Sep 2023
2:27
Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update
Michael Wang • 6 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals